The rate of loss began tapering after week 36, consistent with the metabolic adaptation seen in all obesity pharmacotherapy trials, but the plateau in most participants wasnt reached until approximately weeks 44-48
Medications carry risks and side effects
Tesamorelin Dosing Tesamorelin requires daily subcutaneous injection, typically at a fixed dose rather than escalation protocol
doi: 10.1186/s12974-023-02856-0 397 YaoH.JiangS
no salt, soy, wheat or artificial colors or flavors
We like to set our patients up for success by building strong diet and exercise habits while they are on the medication so that they are losing weight in a healthy way, minimizing the loss of muscle mass, and reducing rebound weight gain when they are ready to discontinue the medication